Anti-HHLA2 antibody (ab214327)
Key features and details
- Rabbit polyclonal to HHLA2
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-HHLA2 antibody
See all HHLA2 primary antibodies -
Description
Rabbit polyclonal to HHLA2 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human HHLA2 aa 250-350 conjugated to keyhole limpet haemocyanin. The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements.
Database link: Q9UM44 -
Positive control
- Human rectal carcinoma tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Proclin 300
Constituents: 50% Glycerol (glycerin, glycerine), 1% BSA, 48.98% TBS, 1X -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab214327 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/500.
|
|
IHC-P |
1/100 - 1/500.
|
Notes |
---|
WB
1/500. |
IHC-P
1/100 - 1/500. |
Target
-
Tissue specificity
Expressed in colon, small intestine, lung and kidney. -
Sequence similarities
Contains 1 Ig-like C1-type (immunoglobulin-like) domain.
Contains 2 Ig-like V-type (immunoglobulin-like) domains. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 11148 Human
- Omim: 604371 Human
- SwissProt: Q9UM44 Human
- Unigene: 252351 Human
-
Alternative names
- B7H7 antibody
- HERV H LTR associating 2 antibody
- HERV-H LTR-associating protein 2 antibody
see all
Images
-
Immunohistochemical analysis of formalin-fixed, paraffin-embedded human rectal carcinoma tissue labeling HHLA2 with ab214327 at 1/200 dilution followed by conjugation to the secondary antibody and DAB staining.
-
All lanes : Anti-HHLA2 antibody (ab214327) at 1/500 dilution
Lane 1 : Lovo cell lysates
Lane 2 : A549 cell lysates
Secondary
All lanes : Conjugated secondary antibody at 1/20000 dilution
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab214327 has been referenced in 8 publications.
- Zhu Y et al. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis. Pathol Res Pract 234:153911 (2022). PubMed: 35489125
- Lv C et al. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer. Front Immunol 13:984172 (2022). PubMed: 36159808
- Xu G et al. HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer. Cancer Cell Int 21:252 (2021). PubMed: 33962626
- Luo M et al. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. J Inflamm Res 14:4217-4228 (2021). PubMed: 34483677
- Fu Y et al. B7-H7 is a prognostic biomarker in epithelial ovarian cancer. Transl Cancer Res 9:5360-5370 (2020). PubMed: 35117901
- Lin G et al. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma. Nephron 141:256-264 (2019). PubMed: 30602154
- Zhu Z & Dong W Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. Onco Targets Ther 11:1563-1570 (2018). PubMed: 29593422
- Shimonosono M et al. The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis. Oncotarget 9:22069-22078 (2018). PubMed: 29774123